Introduction {#sec1-1}
============

Neurodegenerative disorders are debilitating conditions that have an increased incidence with the aging of population. Alzheimer\'s (AD) and Parkinson\'s diseases (PD) are the most common neurodegenerative disturbances. Several biochemical and molecular mechanisms are involved in the AD and PD pathogenesis, such as synaptic dysfunction, neurotrophic impairment, energetic deficit triggered by mitochondrial disorder, oxidative stress and neuroinflammation (O'Brien and Wong, 2011; Serrano-Pozo et al., 2011; Mack et al., 2016).

AD is characterized by a progressive cognitive decline due to a variety of pathological changes in the brain, mainly in the basal forebrain cholinergic neurons (O'Brien and Wong, 2011; Serrano-Pozo et al., 2011). On the other hand, PD is classically known as a chronic and progressive movement disorder related to dopaminergic neurodegeneration of the substantia nigra pars compacta (Gao and Wu, 2016; Hirsch et al., 2016). In both illness, neurotrophic factors play an essential role for the survival of neurons affected by degenerative processes (Bothwell, 2016; Ibanez and Andressoo, 2017).

The alterations in the regulation of specific neurotrophic factors and their receptors seem to be involved in the neurodegeneration. Neurotrophic factors prevent the cell death and support the neuronal proliferation and maturation, enhancing the growth and function of affected neurons in AD and PD (Connor and Dragunow, 1998; Sullivan and O'Keeffe, 2016).

The current therapies for AD and PD focus on managing symptoms and fail to prevent further neurodegeneration. In this way, the neurotrophic factors employment emerged as a therapeutic promise in preclinical models of these disorders. However, their effectiveness in clinical studies remains unclear (Pramanik et al., 2016; Sullivan and O'Keeffe, 2016).

Therefore, this review discusses the main findings related to the neurotrophic factor support in the survival, proliferation and maturation of affected neurons in AD and PD, such as cholinergic and dopaminergic neurons, as well as their putative employment as new therapeutic strategy for management of these diseases.

Neurotrophic Factors {#sec1-2}
====================

Neurotrophic factors comprise essential secreted proteins that have several functions in neural and non-neural tissues, mediating the development, survival and maintenance of peripheral and central nervous system (Bothwell, 2016). These pleiotropic molecules play critical roles both in the neuronal development and neural plasticity during the adulthood (Vilar and Mira, 2016), including the establishment of appropriate contacts with specific target cells through of the axonal growth and guidance control, dendrite development and synaptic plasticity (Ledda and Paratcha, 2016).

Currently, neurotrophic factors can be grouped in three major families: neurotrophins, glial cell line-derived neurotrophic factor (GDNF) family of ligands (GFLs) and neurokines (Bothwell, 2014; Ibanez and Andressoo, 2017). Moreover, unconventional neurotrophic factors, such as cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF), have been studied (Lindahl et al., 2017).

The nerve growth factor (NGF), a protein necessary for the survival and development of peripheral nervous system, was the first discovered member of the neurotrophin family (Levi-Montalcini and Angeletti, 1963). In mammals, this family comprises four structurally-related neurotrophins: NGF, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4, also known as NT-4/5) (Bothwell, 2014).

Neurotrophins initially are synthesized as proneurotrophins, being packaged into secretory vesicles. Proneurotrophins undergo proteolytic cleavage, releasing a N-terminal prodomain peptide and a C-terminal mature protein (Bothwell, 2016). Lee et al. (2001) demonstrated that the proneurotrophins cleavage could occur both in intracellular and extracellular medium. In contrast to neurotrophins, proneurotrophins are not inactive. They act in inducing apoptosis pathway through their interaction to the p75 neurotrophin receptor (p75^NTR^) (Teng et al., 2005; Domeniconi et al., 2007). In this way, proneurotrophins mediate neuronal growth cone retraction and pro-apoptotic actions, mainly during development and pathological conditions (Lee et al., 2001; Teng et al., 2005; Deinhardt et al., 2011; Hempstead, 2014).

The neurotrophins and proneurotrophins activities are mediated by their binding to transmembrane receptor systems: tropomyosin receptor kinase (Trk) family and p75^NTR^. All mature neurotrophins and proneurotrophins bind to a p75^NTR^ However, p75^NTR^ is more effectively activated by proneurotrophins, while the Trk receptors are only activated by mature neurotrophins (Lee et al., 2001; Hempstead, 2014). Three different Trks are described for mammals - TrkA, TrkB and TrkC, which have preferred ligands. TrkA preferentially binds to NGF, BDNF and NT-4 has more affinity to TrkB, and TrkC prefers NT-3. Besides this, NT-3 also binds to TrkA and TrkB, though with lower affinity (Hempstead et al., 1991; Squinto et al., 1991; Benedetti et al., 1993; Bibel et al., 1999; Esposito et al., 2001).

Another family of neurotrophic factors is GFLs, a family of proteins represented by GDNF, neurturin (NRTN), artemin (ARTN), and persephin (PSPN) (Ibanez and Andressoo, 2017). GDNF was the first discovered member of GFLs, being described as a potent neurotrophic factor for survival of midbrain dopaminergic neurons (Lin et al., 1993). The description of GDNF receptors became a target for studies soon thereafter.

Currently, it is known that the actions of GFLs are mediated by binding those to two types of receptors. In summary, each GFL selectively interacts with one of the four members of GDNF family receptor α (GFRα1 to 4). However, GFRα has no intracellular domain, being necessary glycosylphosphatidylinositol (GPI) to anchor the GFL-GFRα complex to plasma membrane (Airaksinen and Saarma, 2002). Once that GFL-GFRα complex is anchored, GFLs acquire high affinity for the canonical receptor tyrosine kinase RET or the neuronal cell adhesion molecule (NCAM). In turn, GFL-GFRα-co-receptors complex activates the downstream signaling. Additionally, GFLs can bind to NCAM directly, inducing neurite outgrowth and synapse formation (Ibanez and Andressoo, 2017).

The family of neurokines, also known as neuropoietic cytokine family, comprises the following members: ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), leukemia inhibitory factor (LIF), neuropoietin (NPN), oncostatin M (OSM), cardiotrophin-like cytokine (CLC), interleukin (IL)-6, IL-11 and IL-27 (Halvorsen and Kaur, 2006). CNTF stands out for supporting the survival of motor, dopaminergic and parasympathetic neurons (Sendtner et al., 1991; Hagg and Varon, 1993; Davey et al., 2000). Of note, LIF supports sensory neurons (Moon et al., 2009). Neurokines mediate their actions mainly through Janus tyrosine kinase-signal transducer and activator of transcription (Jak/STAT) pathway (Halvorsen and Kaur, 2006).

Although structurally and functionally distinct from the classical neurotrophic factors, CDNF and MANF also show neurotrophic properties, such as the promotion of the dopaminergic neurons survival in the midbrain and the maintenance of endoplasmic reticulum homeostasis. However, their mechanisms of action remain largely unclear (Lindahl et al., 2017).

Neurotrophic Factors in AD and PD Pathophysiology {#sec1-3}
=================================================

Neurotrophic factor issue has been extensively investigated into the context of neurodegenerative diseases, particularly AD and PD, because they show alterations in their levels and in adult neurogenesis as common hallmarks (Hoglinger et al., 2004; Gakhar-Koppole et al., 2008; O'Keeffe et al., 2009; Vilar and Mira, 2016). In this way, the understanding of the neurotrophic factor roles in supporting survival, proliferation and maturation of certain neurons, such as cholinergic and dopaminergic neurons, is a focus of active research and also of this review.

Alzheimer\'s disease {#sec2-1}
--------------------

AD is well established as a complex progressive neurodegenerative disorder that results in memory deterioration and cognitive capacity impairment. However, this illness also comprises non-cognitive symptoms, such as delusions, agitation and changes in mood and personality (Epelbaum et al., 2017). The observed symptoms are associated with cholinergic deficits, mainly those related to cognitive functions. AD patients exhibit degeneration in the basal forebrain cholinergic neurons and in their projections for the cortex and hippocampus, being the loss of neurotrophic support a likely involved mechanism (Serrano-Pozo et al., 2011).

Analyses of brains from AD patients demonstrate the presence of β-amyloid peptide aggregates in the extracellular medium, intracellular inclusions of neurofibrillary tangles rich in microtubule-associated protein tau, and neuritic plaques, which are pathological hallmarks of this disease (Serrano-Pozo et al., 2011). Moreover, the β-amyloid toxicity may also explain pathological aspects of AD, such as neurofibrillary tangles, inflammation and oxidative damage (O'Brien and Wong, 2011).

Oxidative stress is inextricably linked with several major pathological processes in AD, including β-amyloid-induced neurotoxicity, tau pathology, mitochondrial dysfunction and metal dyshomeostasis. In addition, oxidative stress plays an important role in the initiation and progression of AD (Zhao and Zhao, 2013). In fact, amyloidosis and tau protein accumulation can induce reactive oxygen species increase that promotes a redox imbalance. In contrast, the oxidative stress could have a causal relation with the AD pathogenesis. In this way, the augment of β-amyloid production and aggregation and tau phosphorylation and polymerization induce the reactive oxygen species increase (Zhao and Zhao, 2013). Notably, the oligomeric form of β-amyloid has been considered the most neurotoxic (Allen et al., 2011).

Additionally, changes in neurotrophic factors are observed both in AD animal models and patients (Allen et al., 2011; Budni et al., 2015). In this context, the neurotrophins NGF and BDNF stand out. NGF is a key neurotrophic factor cholinergic system development, including neuronal survival and differentiation (Nilbratt et al., 2010). It is synthesized in the cortex and hippocampus and retrogradely transported to the basal forebrain cholinergic neurons (Cattaneo and Calissano, 2012). NGF also induces rapid plasticity in the barrel cortex of rats - a region of the primary somatosensory cortex -- through projections to basal forebrain cholinergic system (Prakash et al., 2004). Concerning that the basal forebrain cholinergic neurons constitute the main cholinergic innervation to hippocampus and neocortex, they play an essential role in cognition and attention processes (Triaca and Calissano, 2016). Moreover, Biane et al. (2014) observed that cortical GABAergic neurons are the primary source of NGF synthesis, providing support for basal forebrain cholinergic projections in adulthood.

Regarding AD, postmortem-derived tissue show NGF levels decrease in the nucleus basalis of Meynert, a neuronal group that projects large cholinergic innervation source to widespread cortical areas and it is well known to undergo degeneration in this disorder (Scott et al., 1995). Indeed, there are *in vitro* and *in vivo* evidence suggesting that NGF levels control the amyloidogenic pathway and β-amyloid peptides production (Matrone et al., 2008a, b; Yang et al., 2014). In physiological conditions, amyloid precursor protein (APP) can bind to TrkA. However, phosphorylated APP at Thr668, presents in AD patients, does not interact with TrkA favoring the β-secretase action that, in turn, increases the β-products levels. Thus, NGF controls the amyloidogenic route through the decrease in APP phosphorylation that diminishes the APP-β-secretase interaction by reducing the β-amyloid peptides formation (Triaca et al., 2016).

NGF retrograde transport from cortex and hippocampus to the basal forebrain cholinergic neurons is TrkA dependent. Nevertheless, this transport is dysfunctional in AD (Cattaneo and Calissano, 2012). In this way, decreased TrkA gene expression may be linked to basal forebrain neurodegeneration in early AD patients and increased NGF levels in the cortex of AD postmortem brains (Fahnestock et al., 1996; Counts et al., 2004). In addition, TrkA shows pro-survival or pro-apoptotic actions that are dependent of the presence or absence of NGF. TrkA-mediated pro-death signals were demonstrated after a reduction in NGF levels and as a consequence of overactivation of NGF-TrkA signaling following NGF withdrawal (Li et al., 2010; Nikoletopoulou et al., 2010).

Furthermore, p75^NTR^ expression changes also are reported in the literature. Hippocampal TrkA expression is reduced in mild cognitive impairment patients while pro-NGF is elevated, suggesting the activation of pro-apoptotic pathways by pro-NGF (Mufson et al., 2012). Current data from Crispoltoni et al. (2017) demonstrated changes in the TrkA/p75^NTR^ expressions during the disease progression in monocytic cells, which perform the β-amyloid deposits clearance. Mild cognitive impairment and mild AD patients showed an elevation in TrkA expression in monocytes and in NGF levels in plasma. In contrast, a reduction in both molecules and the monocytic p75^NTR^ expression increase were found in patients with severe AD (Crispoltoni et al., 2017).

Regarding BDNF, this neurotrophin is largely expressed in the central nervous system, influencing several aspects of the neuronal function. Because this, BDNF was established as the main central neurotrophic factor (Park and Poo, 2013). BNDF mediates hippocampal plasticity in adulthood, survival and integration of hippocampal new-born neurons, assists the early and late long term potentiation (LTP) phases and works as cellular substrate for learning and memory (Vilar and Mira, 2016).

Similar to NGF, imbalance in BDNF levels also has been reported in AD cases. BDNF concentrations were found elevated in plasma of patients with severe AD (Angelucci et al., 2010; Faria et al., 2014). However, studies that investigated serum BDNF levels in mild cognitive impairment subjects show conflicting results (Angelucci et al., 2010; Faria et al., 2014). On the other hand, a postmortem study revealed that hippocampal BDNF expression was not altered, while TrkB expression was increased (Kao et al., 2012). In contrast, Ferrer et al. (1999) observed that both BDNF and TrkB levels were reduced in cerebral cortex and hippocampus of AD patients. Recently, the cortical BDNF expression reduction was corroborated by Buchman et al. (2016).

Preclinical reports have described that AD transgenic mouse models show decreased cortical BDNF expression and BDNF-mediated TrkB retrograde trafficking impairment in neuronal culture submitted to β-amyloid peptides (Peng et al., 2009; Poon et al., 2011). Alterations in the anterograde and retrograde transport of BDNF-containing vesicles by extracellular products from APP also were recently demonstrated (Seifert et al., 2016). Additionally, β-amyloid at a sublethal concentration down-regulates the BDNF signaling in cultured cortical neurons (Tong et al., 2004). In contrast, both protein and mRNA levels of BDNF were elevated in cells submitted to β-amyloid~(25--35)~ treatment (Lattanzio et al., 2016).

Data from Lattanzio et al. (2016) are in accordance with the putative causal role of BDNF in the AD pathogenesis. Ruiz-Leon and Pascual (2001) demonstrated that the binding of BNDF to TrkB, in a dose- and time-dependent fashion, can modulate the *in vitro* APP expression. In addition, full activation of APP gene expression by BDNF is simultaneously mediated by Ras/MAPK and PI3K/Akt signaling pathways (Ruiz-Leon and Pascual, 2001, 2004). Once that APP overexpression is an AD risk factor because it increases the β-amyloid peptide levels, BDNF could favor the formation of them. However, the most clinical and preclinical evidence indicates a BDNF reduction in the AD affected brain areas. Thus, these findings suggest a physiological role of APP in the cellular growth, which may be modulated by factors other than BDNF. Of note, these outcomes also present an open question for establishing the mechanisms undertaken by APP.

Parkinson\'s disease {#sec2-2}
--------------------

PD is the second most common neurodegenerative disorder after AD. The PD incidence rate rises with the age, being expected a social and economic burden on the societies that prevalently have elderly population (Hirsch et al., 2016; Mack et al., 2016). PD etiology shows that although the most of patients are idiopathic or late onset PD cases (\> 85 %), there is a relation between familial historic and a high PD risk. Additionally, families with inherited parkinsonism (\< 10 %) had a variety of putative genes involved in PD identified individuals, showing that mitochondrial or lysosomal dysfunctions, protein aggregation, ubiquitin-proteasome system and kinase signaling pathways play a major role in the PD pathogenesis (Corti et al., 2011).

PD is clinically characterized by resting tremor, rigidity, bradykinesia and postural instability. Furthermore, nonmotor symptoms also are observed, occurring both in the late and early stages. These nonmotor symptoms comprise olfactory deficits, constipation, sleep behavior disorders, cognitive impairment and mood disturbances, such as anxiety and depression (Chaudhuri et al., 2006; Mack et al., 2016).

The disability of PD patients controlling the voluntary movements is a consequence of changes in the functional organization of the basal ganglia nuclei, which include the dopaminergic neurons loss in the substantia nigra pars compacta resulting in dopaminergic deficiency in the striatum (Gao and Wu, 2016). The major pathological hallmarks of PD comprise the presence of dystrophic neurites and Lewy bodies --intracytoplasmic inclusions in the surviving neurons composed mainly by α-synuclein and ubiquitin proteins (Wakabayashi et al., 2007).

Furthermore, neurotrophic factor alterations also are observed both in pre-clinical and clinical PD studies. In general, decreased neurotrophic factor levels have been reported in dopaminergic areas linked to PD, such as the substantia nigra (Nagatsu and Sawada, 2007). More consistent evidence suggests the major BDNF and GDNF involvement in the PD pathophysiology (Howells et al., 2000; Chauhan et al., 2001; Nagatsu and Sawada, 2007). Moreover, CDNF and MANF have emerged as new targets of study for this illness (Lindahl et al., 2017).

Accumulating data indicate the essential role and wide expression of BDNF in central motor structures, for instance basal ganglia, cerebellum and brainstem (Altar et al., 1997; He et al., 2013). So, disturbance in its homeostasis is harmful for neuronal development and survival in these areas (Li et al., 2012). Its neurotrophic functions include development and differentiation of cerebellar granule and Purkinje cells (Schwartz et al., 1997), survival support for dopaminergic neurons in the ventral tegmental area and medial substantia nigra pars compacta (Hyman et al., 1991; Baquet et al., 2005), and nigrostriatal apoptosis inhibition by BDNF/TrkB signaling (Lui et al., 2012). Moreover, the expressions of dopamine D3 receptor and tyrosine hydroxylase are mediated by BDNF (Du et al., 1995; Guillin et al., 2001).

Postmortem studies of PD patients found a reduction in the BDNF levels and in its expression in the substantia nigra pars compacta, caudate nucleus and putamen (Mogi et al., 1999; Parain et al., 1999; Howells et al., 2000; Nagatsu and Sawada, 2007). In addition, decreased BDNF levels is positively correlated to the degree of dopaminergic degeneration (Ziebell et al., 2012). Interestingly, genetic polymorphism of BDNF influences on familial PD, cognitive performance in individuals with PD and in the development of L-DOPA-induced dyskinesias (Foltynie et al., 2005; Karamohamed et al., 2005; Evans and Barker, 2008). Moreover, the α-synuclein overexpression down-regulates BDNF transcription and impairs BDNF trafficking in neurons (Yuan et al., 2010; Chu et al., 2012; Pramanik et al., 2016).

On the other hand, preclinical studies carried out in animal models show unclear results linked to BDNF levels imbalance. Hence, several factors can influence BDNF levels in PD models, for instance, the neurotoxin used, the administration protocol chosen and the degree of dopaminergic damage induced (Collier et al., 2005; Mocchetti et al., 2007; Berghauzen-Maciejewska et al., 2015; Sampaio et al., 2017).

Similar to BDNF, GDNF also assists motor and dopaminergic neurons, having an important role in their survival, differentiation, organization and maintenance (Henderson et al., 1994; Evans and Barker, 2008; Chermenina et al., 2014). Nevertheless, GDNF is five to ten times more potent than BDNF for survival promotion in injured nigrostriatal neurons of rats (Lu and Hagg, 1997). Adult mice express GDNF only in the dorsal and ventral striatum, anteroventral nucleus of the thalamus, septum and subcommissural organ (Pascual et al., 2011), whereas RET and GFRα1 are broadly expressed in the central nervous system (d'Anglemont de Tassigny et al., 2015). Curiously, there is no GDNF receptors mRNAs in the striatum, but high expression of them in the nigral cells (Trupp et al., 1997) suggesting a specific action on nigral dopaminergic neurons. Due to robust preclinical evidence of its effects, GDNF is one of the most largely investigated neurorestorative approach for PD.

Besides that, clinical reports also have related GDNF with the dopaminergic system. High expression of GDNF and RET were found in human striatum and substantia nigra, respectively (Springer et al., 1994; Trupp et al., 1997). Furthermore, Chauhan et al. (2001) demonstrated that the nigral GDNF reduction in brain of PD patients was of two to eight times greater than those of other neurotrophic factors analyzed. Nevertheless, in another postmortem study in lysates of caudate/putamen, substantia nigra, cerebellum, frontal cortex and cerebrospinal-fluid, no significant difference was found between healthy subjects and PD patients (Mogi et al., 2001). Moreover, the detected polymorphisms in the GDNF gene did not show correlation with the disease (Wartiovaara et al., 1998).

CDNF and MANF have emerged in the PD context due to their neurotrophic effects on dopaminergic neurons. Low levels of CDNF expression have been detected in most of the brain areas of embryonic, postnatal and adult mouse, whereas CDNF levels were mainly observed in neurons of adult mouse. Nevertheless, CDNF immunocontent is not colocalized with tyrosine hydroxylase-positive cells in the substantia nigra. Indeed, few CDNF-positive neurons were stained in the substantia nigra and striatum, being more abundant in cerebellum, locus coeruleus, hippocampus and thalamus. Furthermore, CDNF expression was observed in the human brain and in central and peripheral non-neuronal tissues (Lindholm et al., 2007).

In contrast to CDNF, MANF expression was found in several areas of the developing and adult brain, including striatum and midbrain (Lindholm et al., 2008; Wang et al., 2014). In addition, its immunocontent presented colocalization with dopaminergic neurons in the substantia nigra (Lindholm et al., 2008). Although no effects on dopaminergic neurons are observed when MANF is administered in naïve rodents, accumulating evidence suggests its neurorestorative role against injured neurons (Airavaara et al., 2009; Voutilainen et al., 2009). Moreover, MANF regulates the endoplasmic reticulum stress and unfolded protein response (Apostolou et al., 2008).

Although several aspects linked to physiology of CDNF and MANF, such as their cytoprotective mechanism and their ability to bind to transmembrane receptors (Lindahl et al., 2017) remain unclear, their beneficial effects against *in vitro* and *in vivo* PD experimental models justify the growing investigation about them.

Neurotrophic Factors as Therapy Strategies for AD and PD {#sec1-4}
========================================================

Besides the role of neurotrophic factors in the nourishment, survival and regeneration of neurons, there is increasing evidence indicating their involvement in the survival, anti-inflammation, proliferation and differentiation of non-neuronal tissues (Bothwell, 2016). In addition, they can be found in tissue-specific adult stem cell niche, inducing tissue regeneration outside the nervous system (Matsuda et al., 1988; Meng et al., 2000; Lavasani et al., 2006). Considering these evidence and the pathophysiological features that link the neurotrophic factors to AD and PD, it is plausible the neurotrophic factors employment as therapeutic approach for neuroregeneration.

The current therapies for AD and PD are initially effective, alleviating the main symptoms of these diseases. However, disease progression is not prevented, justifying the research focus in neurorestorative approaches. In this way, pluripotent stem cells transplant, gene therapy vectors, neurotrophic factor replacement and neurotrophic factor mimetics emerge as strategies for neuronal regeneration. In contrast to current therapies, these new therapeutic strategies could provide a cure for neurodegenerative disorders.

Across the last decades, research data on the therapeutic promise of neurotrophic factors have been collected. Nevertheless, none treatment for any disease was established. Firstly, different neurotrophic factors were tested by subcutaneous route, in order to produce a systemic exposure (Group, 1999; Sorenson et al., 2008). Following serious side effects found with the subcutaneous injections, intrathecal delivery of neurotrophic factors, mainly CNTF and BDNF, was employed. Intrathecal administration avoided subcutaneous side effects, indicating the feasibility and tolerability by this delivery route. Lumbar and cervical taps analysis demonstrated the ability of neurotrophic factors to be distributed in the cerebrospinal-fluid compartment following intrathecal infusion. However, the effectiveness of these proteins to reach the spinal cord and brain was not elicited. Moreover, unexpected side effects likely dose-related were found subsequently to intrathecal administration (Aebischer et al., 1996; Penn et al., 1997; Ochs et al., 2000; Kalra et al., 2003; Beck et al., 2005).

Dosing paradigm for neurotrophic factor intrathecal administration was changed after the results obtained from intracerebral ventricular (ICV) infusion of neurotrophic factors, which suggested that cerebrospinal-fluid was not the ideal way to delivery these peptides. ICV studies using NGF and GDNF, respectively, in AD and PD patients, demonstrated significant side effects with little clinical benefit (Eriksdotter Jonhagen et al., 1998; Kordower et al., 1999; Nutt et al., 2003). In addition, dose reduction was enough to eliminate side effects observed in the ICV approach. In this way, intrathecal approach, which also reaches the cerebrospinal-fluid compartment, may yet prove useful for application of new strategies with different biological constructs, for instance, antisense oligonucleotides, some gene therapy vectors and phage-like entities (Bartus and Johnson, 2017).

Based on findings from previous trials, neurotrophic factors began to be administered directly into the target tissue. As in the pioneer study that tested NGF into the putamen of a PD patient (Olson et al., 1991), positive clinical effects have been reported using GDNF in PD subjects, without serious side effects (Gill et al., 2003; Love et al., 2005; Patel et al., 2005, 2013). Besides the enhanced performance in standardized PD scales and tests, improvement in \[18F\]-dopamine uptake after a year of treatment was described (Gill et al., 2003). Additionally, an autopsied brain from a study by Gill et al. (2003) showed an increase in tyrosine hydroxylase-staining at the injection area of putamen and an enhancement in L-DOPA uptake in the infused hemisphere (Love et al., 2005). However, a double-blind controlled trial with PD patients did not replicate those clinical outcomes (Lang et al., 2006). These conflicting data were attributed to putative differences in drug delivery (Salvatore et al., 2006). Nevertheless, Morrison et al. (2007) reported that GDNF distribution and diffusion did not explain the different efficacy found.

Regarding clinical trials of AD, investigators were focused on developing effective and innovative delivery methods. Gene transfer has emerged as a technology able to provide controlled, predictable, long-term biologically active proteins, which act on specific targeted brain sites (Herzog et al., 2011). Autologous fibroblasts genetically modified to express human NGF were implanted into the basal forebrain area of AD patients. The subjects showed an improvement in the cognitive decline rate and an increase in cortical 18-fluorodeoxyglucose, indicating metabolic activity in this area (Tuszynski et al., 2005). Autopsied brain confirmed long-term, targeted, gene-mediated NGF expression and bioactivity (Rafii et al., 2014). In addition, it was observed that axons sprouted toward the local source of NGF and cell hypertrophy (Tuszynski et al., 2015).

Preclinical studies also have used innovative delivery methods to evaluate the neurotrophic factors potential against AD models. Recombinant lentiviral vectors used to overexpress hippocampal GDNF gene in astrocytes preserved cognitive functions in 3xTg-AD mice and aged rats (Pertusa et al., 2008; Revilla et al., 2014). Revilla et al. (2014) also reported that MC65 cells overexpressing GDNF presented a reduction of toxic APP content and its β-amyloid peptides-derived. Moreover, protective effect of GDNF against β-amyloid-induced neuronal death was demonstrated in rabbit hippocampus and in cultured septal neurons (Ghribi et al., 2004; Kitiyanant et al., 2012). Although these data are promising, further preclinical and clinical studies are needed to elucidate the putative application of GDNF as therapeutic strategy for AD.

Conclusion {#sec1-5}
==========

In summary, neurotrophic factors play essential roles for survival, development and maintenance of neurons. Alterations in the neurotrophic factors levels/expression and their signaling pathways seem to be tied to the development and/or progression of neurodegenerative disorders. In this context, neurotrophic factors emerge as therapeutic promises for AD and PD. Although many data have been collected in the last decades, none neurotrophic factor treatment for any disease was established until now. However, the new drug delivery approaches, such as gene therapy vectors, search to optimize the clinical benefit in reducing the side effects observed in the tested methods. Thus, application of neurotrophic factors using new therapeutic methods should be carefully considered and evaluated for AD and PD management.
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